Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell 5Arthritis, Rheumatoid 5Solid Tumors 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Colorectal Neoplasms 3Ovarian Neoplasms 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spondylitis, Ankylosing 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Esophageal Neoplasms 1

Interventions

Adalimumab 2tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Spondylitis, Ankylosing × tocilizumab × Clear all
NCT01209689 2013-01-17

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Hoffmann-La Roche

Phase 3 Terminated
113 enrolled 7 charts

Spondylitis, Ankylosing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡